Research and Practice in Thrombosis and Haemostasis最新文献

{"title":"179 Direct Oral Anticoagulants in End State Renal Disease","authors":"Avani Prabhu , Bhakti Singh , Anvi Peddi , Haritha Pabbathi , Atul Laddu , Jawed Fareed","doi":"10.1016/j.rpth.2025.102829","DOIUrl":"10.1016/j.rpth.2025.102829","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 ","pages":"Article 102829"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"183 Women in Science","authors":"Isha Jayakumar , Nila Jayakumar , Srishti Sawant , Gitika Aggarwal , Atul Laddu , Jawed Fareed","doi":"10.1016/j.rpth.2025.102832","DOIUrl":"10.1016/j.rpth.2025.102832","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 ","pages":"Article 102832"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"171 Pharmacy-driven Antithrombosis Stewardship Consultation to Promote Safe, Timely Discharge of Low-Risk Venous Thromboembolism from the Emergency Department (PASS ON ADMIT Study)","authors":"Juan D. Castellanos , Preeyaporn Sarangarm , Lisa Koselke , Allison E. Burnett","doi":"10.1016/j.rpth.2025.102759","DOIUrl":"10.1016/j.rpth.2025.102759","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 ","pages":"Article 102759"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"134 Evaluation of Antiseizure Medication Impact on Efficacy of Direct Oral Anticoagulants","authors":"Corinne M. Bertolaccini , Lauren Bronson , Tara K. Lech","doi":"10.1016/j.rpth.2025.102817","DOIUrl":"10.1016/j.rpth.2025.102817","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 ","pages":"Article 102817"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"56 Analysis of Xa Levels and PTTs During the First 48 Hours of Anticoagulation with Unfractionated Heparin Infusion","authors":"Kaitlyn Loi","doi":"10.1016/j.rpth.2025.102826","DOIUrl":"10.1016/j.rpth.2025.102826","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 ","pages":"Article 102826"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"151 Improving the Perioperative Process for Patients Managed by a Pharmacist-Run Anticoagulation Clinic","authors":"Sanela Lekic , Katie Kish , Kayla Woicehovich , Amita Pandya , Brandy Ungham , Nicole Bonnallie , Angela Sanders","doi":"10.1016/j.rpth.2025.102743","DOIUrl":"10.1016/j.rpth.2025.102743","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 ","pages":"Article 102743"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"79 Safety Huddles in Anticoagulation Clinic Practice","authors":"Abbie M. Helmrick , Christina M. Bookwalter","doi":"10.1016/j.rpth.2025.102748","DOIUrl":"10.1016/j.rpth.2025.102748","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 ","pages":"Article 102748"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of the international classification of disease “I26” code to detect acute pulmonary embolism in a surveillance network","authors":"Jeffrey A. Kline ,&nbsp;Jesse O. Wrenn ,&nbsp;Mazin F. Alam ,&nbsp;Alexis N. Drinkhorn ,&nbsp;Conner D. Slotnick ,&nbsp;Fawas Shaman ,&nbsp;Christopher E. Conn ,&nbsp;Steven J. Korzeniewski ,&nbsp;Christopher Kabrhel","doi":"10.1016/j.rpth.2025.102900","DOIUrl":"10.1016/j.rpth.2025.102900","url":null,"abstract":"<div><h3>Background</h3><div>Emergency departments (EDs) offer a unique platform for a surveillance network for acute pulmonary embolism (PE) using International Classification of Disease (ICD-10) codes extracted from electronic medical records.</div></div><div><h3>Objectives</h3><div>Test the diagnostic accuracy of the I26 \"leader\" ICD-10 code for the detection of PE in near real-time in a large, ED-based surveillance network.</div></div><div><h3>Methods</h3><div>Standardized structured language queries were deployed at 91 hospitals to extract data, including ICD-10 codes, on a weekly basis from electronic medical records on ED patients with acute respiratory complaints. We used 2 methods for coding computed tomography pulmonary angiogram (CTPA) reports to derive a criterion or gold standard for PE diagnosis: (1) research associates were trained to interpret the CTPA reports, and (2) a validated Regular Expression computer program was used to interpret PE on CTPA reports. These 2 methods were independently adjudicated (PE⁺ or PE⁻). The primary outcome was diagnostic accuracy of the I26 leader compared with the final adjudication.</div></div><div><h3>Results</h3><div>From 6448 valid CTPA scan reports, 442 (6.8%) were adjudicated as PE⁺. On a weekly basis, the I26 leader had a sensitivity of 50.9% (95% CI, 46.1%-55.6%) and a specificity of 99.7% (95% CI, 99.5%-99.8%), likelihood ratio (LR) negative of 0.49 (95% CI, 0.44-0.54) and LR positive of 191 (95% CI, 116-12). At 1 month, the I26 sensitivity was 57.5% (95% CI, 52.7%-62.1%), and specificity was 99.5% (95% CI, 99.2%-99.6%); LRnegative of 0.43 (95% CI, 0.38-0.47) and LRpositive of 111 (95% CI, 77-159).</div></div><div><h3>Conclusion</h3><div>For low-latency surveillance of PE diagnosed in EDs, the ICD leader code I26 affords high specificity and high LR(+) for detection of acute PE in the United States but has modest sensitivity.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 4","pages":"Article 102900"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144271368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for anticoagulation in patients with thrombocytopenia and cancer-associated thrombosis (START): design and rationale of the START pilot randomized controlled trial","authors":"Tzu–Fei Wang ,&nbsp;Mari Thomas ,&nbsp;Andrea Cervi ,&nbsp;Yishi Tan ,&nbsp;Cynthia Wu ,&nbsp;Avi Leader ,&nbsp;Luis Jara–Palomares ,&nbsp;Simon J. Stanworth ,&nbsp;Marc Carrier","doi":"10.1016/j.rpth.2025.102898","DOIUrl":"10.1016/j.rpth.2025.102898","url":null,"abstract":"<div><div>Patients with cancer have high risks of venous thromboembolism (VTE) as well as thrombocytopenia. Thrombocytopenia is associated with an increased risk of bleeding. Hence, treatment of acute VTE with anticoagulation is challenging in patients with cancer and thrombocytopenia. Data are limited in the management of this condition, and there are no randomized controlled trials (RCTs) available. The strategies for anticoagulation in patients with thrombocytopenia and cancer-associated thrombosis pilot trial (NCT05255003) is an open-label pilot RCT to evaluate the feasibility of a full-scale trial in this population. Adult patients with acute cancer-associated thrombosis within 14 days and thrombocytopenia (platelet count &lt; 50,000/μL) are randomly assigned to 2 treatment arms as follows: (1) modified-dose low-molecular-weight heparin based on a predefined regimen to adjust dose by platelet count; or (2) platelet transfusion with a higher dose low-molecular-weight heparin regimen. The primary feasibility outcome is the overall average number of patients recruited per month. The main clinical outcomes include clinically relevant bleeding events (composite of major bleeding and clinically relevant nonmajor bleeding) and objectively confirmed recurrent VTE. This trial has the potential to define care in patients with acute cancer-associated thrombosis and thrombocytopenia. In this article, we present the rationale and design of the pilot trial and highlight several unique aspects of the study.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 4","pages":"Article 102898"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144313451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene-based therapies for hemophilia","authors":"Melissa F. Glasner ,&nbsp;Steven Pipe ,&nbsp;Wolfgang Miesbach","doi":"10.1016/j.rpth.2025.102870","DOIUrl":"10.1016/j.rpth.2025.102870","url":null,"abstract":"<div><div>Gene therapy is a transformative approach to treating genetic disorders in order to improve disease outcomes for patients. Hemophilia A and B are inherited genetic disorders caused by mutations in the <em>FVIII</em> and <em>FIX</em> genes, respectively. Traditional treatments for hemophilia have included intravenous plasma, factor concentrates, and nonfactor therapies that require lifelong prophylaxis and carry risks of factor inhibitor development. Gene therapy offers a novel solution by delivering functional <em>FVIII</em> or <em>FIX</em> genes via adeno-associated virus vectors, which enable the production of the missing factors. Clinical outcomes have shown promise through gene therapies like valoctocogene roxaparvovec for hemophilia A and etranacogene dezaparvovec and fidanacogene elaparvovec for hemophilia B. Each therapy has demonstrated efficacy in reducing bleeding rates and maintaining factor activity. However, challenges such as hepatotoxicity, immune response, and durability of gene expression persist. Future advancements aim to expand eligibility, achieve sustained expression, and minimize adverse effects. Current trials are exploring new vectors, transgenes, and methods to overcome existing limitations. Gene therapy holds the potential to revolutionize hemophilia treatment, offering a path toward long-term management and improved quality of life for patients.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 4","pages":"Article 102870"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}